Finerenone increases the likelihood of improved KDIGO risk category in patients with CKD and type 2 diabetes: An analysis from FIDELITY

Finerenone improves KDIGO risk category for renal function in patients with CKD and type 2 diabetes.
Specifically, individuals treated with finerenone had a notable improvement in outcomes related to chronic kidney disease.

Does finerenone improve KDIGO risk category in patients with CKD and type 2 diabetes?

Population

Patients with CKD and type 2 diabetes

Intervention

Finerenone

Outcome

Improved KDIGO risk categorysurrogate

Finerenone increases the likelihood of improved KDIGO risk category in patients with CKD and type 2 diabetes.

FIDELIO-DKD (NCT02540993) and FIGARO-DKD (NCT02545049) are registered with ClinicalTrials.gov (funded by Bayer AG).

Cite This Study